Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 168

The DOI matches its Crossref record.

PHASE I TRIAL OF 16 FORMULATIONS OF A TETRAVALENT LIVE-ATTENUATED DENGUE VACCINE

EDELMAN, ROBERT, WASSERMAN, STEVEN S., BODISON, SACARED A., PUTNAK, ROBERT J., ECKELS, KENNETH H., TANG, DOUGLAS, KANESA-THASAN, NIRANJAN, VAUGHN, DAVID W., INNIS, BRUCE L., SUN, WELLINGTON·2003·The American Journal of Tropical Medicine and Hygiene

Abstract

Laboratory-attenuated strains of each of the four dengue serotypes previously tested as monovalent vaccines in volunteers were combined and tested for immunogenicity, safety, and reactogenicity in 16 dosage combinations. Tetravalent vaccines made using combinations of high (10 5–6 plaque-forming units [PFU]/dose) or low (10 3.5–4.5 PFU/dose) dosage formulations of each of the four viruses were inoculated in 64 flavivirus non-immune adult volunteers to determine which, if any, formulation raised neutralizing antibodies in at least 75% of volunteers to at least three of four dengue serotypes following one or two inoculations. Such formulations, if safe and sufficiently non-reactogenic, would be considered for an expanded Phase II trial in the future. Formulations 1–15 were each inoculated into three or four volunteers (total = 54) on days 0 and 28. Formulation 16 was tested in 10 volunteers, five volunteers inoculated on days 0 and 30, one volunteer on days 0 and 120, and four volunteers on days 0, 30, and 120. Blood was drawn for serologic assays immediately before and one month after each vaccination, and for viremia assay on day 10 after each vaccination. The 16 formulations were safe, but variably reactogenic after the first vaccination, and nearly non-reactogenic after the second and third vaccinations. Reactogenicity was positively correlated with immunogenicity. Similar proportions of volunteers seroconverted to dengue-1 (69%), dengue-2 (78%), and dengue-3 (69%), but significantly fewer volunteers seroconverted to dengue-4 (38%). The geometric mean 50% plaque reduction neutralization test titers in persons who seroconverted were significantly higher to dengue-1 (1:94) than to dengue-2 (1:15), dengue-3 (1:10), and dengue-4 (1:2). Seven formulations met the serologic criteria required for an expanded trial, and three of these were sufficiently attenuated clinically to justify further testing.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.4269/ajtmh.2003.69.48

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 168

Metadata

Authors
EDELMAN, R., WASSERMAN, S. S., BODISON, S. A., PUTNAK, R. J., ECKELS, K. H., TANG, D., KANESA-THASAN, N., VAUGHN, D. W., INNIS, B. L., & SUN, W.
Venue
The American Journal of Tropical Medicine and Hygiene
Published
2003-12
Volume
69
Issue
6_suppl
Pages
48-60
ISSN
0002-9637 (ISSN-L)
OpenAlex
W2124109048
Cited by
168
References
0
FWCI
9.89
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: PHASE I TRIAL OF 16 FORMULATIONS OF A TETRAVALENT LIVE-ATTENUATED DENGUE VACCINE. https://app.cochat.ai/papers/10.4269/ajtmh.2003.69.48
The paper
EDELMAN, R., WASSERMAN, S. S., BODISON, S. A., PUTNAK, R. J., ECKELS, K. H., TANG, D., KANESA-THASAN, N., VAUGHN, D. W., INNIS, B. L., & SUN, W. (2003). PHASE I TRIAL OF 16 FORMULATIONS OF A TETRAVALENT LIVE-ATTENUATED DENGUE VACCINE. The American Journal of Tropical Medicine and Hygiene. https://doi.org/10.4269/ajtmh.2003.69.48

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.